Skip to content

Interstitial Lung Diseases Cohort Study in China

Interstitial Lung Diseases Cohort Study in China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04370158
Acronym
ILD-China
Enrollment
3000
Registered
2020-04-30
Start date
2016-07-01
Completion date
2020-12-31
Last updated
2020-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Diseases

Brief summary

In this project, the clinical diagnosis of interstitial lung diseases was carried out for the population with suspected interstitial lung diseases selected from the community cohort, and the confirmed patients were included into the existing clinical cohort of interstitial lung diseases, forming an interstitial lung diseases special disease cohort consisting of 3,000 patients and corresponding matched control groups. According to characteristics of interstitial lung disease and the needs of National Key R&D Program of China, this study will formulate unified clinical follow-up strategy to do long-term standardized clinical follow-up in patients with interstitial lung disease. The detailed information for clinical diagnosis and treatment as well as biological samples were collected to identify disease phenotype and build the database and biological sample library for interstitial lung disease cohort study. This study aims to provide evidence for molecular classification, screening and validation of biomarkers as well as precise diagnosis and prevention in patients with interstitial lung disease.

Interventions

Clinical progression and prognosis of patients with interstitial lung diseases

Sponsors

The First Affiliated Hospital of Guangzhou Medical University
CollaboratorOTHER
Xiangya Hospital of Central South University
CollaboratorOTHER
First Hospital of China Medical University
CollaboratorOTHER
The Fourth Affiliated Hospital of China Medical University
CollaboratorOTHER
Peking Union Medical College Hospital
CollaboratorOTHER
China-Japan Friendship Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Physician diagnosed IPF during the last 3 months based upon ATS/ERS/JRS/ALAT guidelines 2011 * Agree to sign the informed consent

Exclusion criteria

* Lung transplantation expected within the next 6 months

Design outcomes

Primary

MeasureTime frameDescription
Database and biological sample library for Chinese patients with interstitial lung diseaseup to 4 yearsData analyses will be mainly descriptive.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026